Gilead gets US FDA Accelerated Approval for Trodelvy to treat metastatic urothelial cancer
New indication marks secondFDAapproval for Trodelvy in 2021
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Trodelvy
Gilead gets US FDA nod for Trodelvy to treat metastatic triple-negative breast cancer
Trodelvy significantly reduced the risk of death by 49 per cent compared with single-agent chemotherapy in the Phase 3 ASCENT…
Trodelvy from Immunomedics gets US FDA orphan drug designation for glioblastoma
Trodelvy has shown encouraging activity in an early-stage study in brain cancers, including partial responses in small cohorts of…
Trodelvy from Immunomedics extends survival in breast cancer patients
The FDA granted the drug accelerated approval for its use in metastatic triple-negative breast cancer (mTNBC) patients who had…
Gilead may soon buy Immunomedics in deal over $20 billion
The deal, which will expand Gilead’s oncology portfolio, might get announced tomorrow if not sooner, inform reports
FDA approves new therapy for triple negative breast cancer that has spread, not responded to other…
The FDA granted approval of Trodelvy to Immunomedics